Roseville, MN – Monday, February 7, 2022 – Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced that Gerry Nuovo has joined Calyxt as Senior Vice President of Business Development. He brings more than 30 years of experience in the specialty chemicals and biotechnology industries and diverse experience building multimillion-dollar income streams in the personal care and home care markets. Mr. Nuovo will be responsible for business development functions, including potential partnerships, deal structures, valuation models, and subsequent transaction execution and alliance management.
“We’re thrilled to welcome Gerry at this exciting time for our team,” said Michael A. Carr, President and Chief Executive Officer of Calyxt. “His experience is well aligned with our strategy to deliver plant-based synthetic biology solutions to important new customers in identified key end markets, and his track record in cosmetics, nutraceuticals and beauty is particularly timely as we continue to focus our business development efforts on these and other key markets, helping customers produce products that meet their corporate sustainability goals.”
“Calyxt is a synthetic biology company that delivers unique and innovative plant-based solutions not available through other production methods, and the integration of its proprietary PlantSpring™ technology platform with its BioFactory™ production system, enables Calyxt to rapidly prototype and produce complex plant-derived compounds,” said Mr. Nuovo. “It’s a compelling and differentiated offering for customers, and I look forward to working alongside this dynamic executive team.”
Mr. Nuovo most recently served as Vice President of Commercialization & Global Business Development at C16 Biosciences, where he led global commercialization of its novel technology platform focused on an alternative to conflict agricultural palm oil and downstream derivatives. Prior, he served as Sales Director, Americas, Personal Care at Cargill, Inc. and as Vice President, Global Market Development, Consumer Products at Rivertop Renewables. Previously, Mr. Nuovo held senior business development and sales roles at Segetis, Codexis, Inc., and Firmenich, Inc.
Mr. Nuovo holds a B.S. in Biology and Chemistry from William Paterson University of New Jersey.
Calyxt (Nasdaq: CLXT) is a plant-based synthetic biotechnology company. The Company leverages its proprietary PlantSpring™ technology platform to engineer innovative materials and products for its customers to help them meet their sustainability goals. Calyxt’s diversified offerings are primarily delivered through its proprietary BioFactory™ production system. For more information, visit www.calyxt.com.
PlantSpring, BioFactory, Plant Cell Matrix™, and the Calyxt logo are trademarks of Calyxt, Inc. Any other trademarks belong to their respective owners.
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “predicts,” “projects,” “should,” “targets,” “will,” or the negative of these terms and other similar terminology. Forward-looking statements in this press release include statements about Calyxt’s product pipeline and development; Calyxt’s ability to utilize the BioFactory to engineer precursor molecules and to convert these to broader chemistries demanded by potential customers; Calyxt’s ability to achieve target molecule production and performance at greater scale; and the commercial demand for Calyxt’s synthetic biology solutions. These and other forward-looking statements are predictions and projections about future events and trends based on Calyxt’s current expectations, objectives, and intentions and are premised on current assumptions. Calyxt’s actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: the impact of increased competition, including competition from a broader array of synthetic biology companies; disruptions at Calyxt’s key facilities, including disruptions impacting its BioFactory production system; changes in customer preferences and market acceptance of Calyxt’s products; competition for customers, partners, and licensees and the successful execution of development and licensing agreements; the impact of adverse events during development, including unsuccessful pilot production of compounds or generation of inconsistent data; disruptions to supply chains, including raw material inputs for Calyxt’s BioFactory; the impact of changes or increases in oversight and regulation; disputes or challenges regarding intellectual property; proliferation and continuous evolution of new technologies; and other important factors discussed under the caption entitled “Risk Factors” in Calyxt’s Annual Report on Form 10-K and subsequent filings on Form 10-Q or Form 8-K with the U.S. Securities and Exchange Commission. Any forward-looking statements made by Calyxt’s management are based only on information currently available to it when, and speak only as of the date, such statement is made. Calyxt does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.